Ginkgo Bioworks faces ongoing revenue declines and high cash burn, despite cost-cutting efforts and partnerships with major firms like Pfizer and Merck. The company's Q3 2024 revenue was inflated ...

The first stage of the review process is a draft chemical risk assessment. We have completed the draft assessment of Gingko biloba extract. We’re proposing that it may be harmful to human health when ...